Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial.

ABSTRACT:

Importance

Local failure after chemoradiotherapy (CT-RT) significantly contributes to mortality in patients with locally advanced non-small cell lung cancer (LA-NSCLC). One approach to improve local control is through targeted radiosensitization of the tumor.

Objective

To evaluate the dose-limiting toxic effects, maximally tolerated dose, and recommended phase 2 dose of the protease inhibitor nelfinavir mesylate, administered concurrently with CT-RT in patients with LA-NSCLC, and, in the phase 2 portion of the study, to estimate the objective response rate, local and distant failure rates, and overall survival.

Design, setting, and participants

This prospective, open-label, single-group, single-institution phase 1/2 trial tested the oral protease inhibitor nelfinavir

SUBMITTER: Rengan R 

PROVIDER: S-EPMC6707020 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature